|PDL BioPharma, Inc.|
932 Southwood Boulevard
United States - Map
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. has license agreements with various biotechnology and pharmaceutical companies, as well as acquires royalty and other assets. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
|PDL BioPharma, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 4. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 4; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. John Peter McLaughlin J.D.,
Chief Exec. Officer, Pres, Director, Member of Litigation Committee and Member of Compliance Committee
|Mr. Peter S. Garcia ,
Chief Financial Officer and VP
|Mr. Steffen Pietzke CPA,
Chief Accounting Officer and Controller
|Mr. Christopher L. Stone J.D.,
VP, Gen. Counsel and Sec.
|Mr. Danny J. Hart Jr., J.D.,
VP of Bus. Devel.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|